NASDAQ:CBIO Catalyst Biosciences (CBIO) Stock Forecast, Price & News $0.49 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.49▼$0.5250-Day Range$0.33▼$0.6552-Week Range$0.19▼$0.74Volume105,048 shsAverage Volume363,560 shsMarket Capitalization$18.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Biosciences MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.16) to ($0.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.27 out of 5 starsMedical Sector934th out of 965 stocksPharmaceutical Preparations Industry445th out of 456 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Catalyst Biosciences. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Catalyst Biosciences have been sold short.Short Interest Ratio / Days to CoverCatalyst Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalyst Biosciences has recently increased by 61.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Biosciences does not currently pay a dividend.Dividend GrowthCatalyst Biosciences does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Biosciences has received a 57.94% net impact score from Upright. Catalyst Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Biosciences is -0.62. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Catalyst Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Catalyst Biosciences is held by insiders.Percentage Held by InstitutionsOnly 5.98% of the stock of Catalyst Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Catalyst Biosciences are expected to grow in the coming year, from ($0.16) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Biosciences (NASDAQ:CBIO) StockCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Read More CBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBIO Stock News HeadlinesAugust 23, 2023 | finance.yahoo.comIs Catalyst Biosciences (CBIO) Significantly Overvalued?August 22, 2023 | investing.comCatalyst Biosciences (CBIO) Earnings Dates & ReportsSeptember 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.June 9, 2023 | finance.yahoo.comCBIO - Catalyst Biosciences, Inc.April 28, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRTApril 3, 2023 | finance.yahoo.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 monthsMarch 31, 2023 | insidermonkey.com5 Cheap Healthcare Stocks to Buy in 2023March 31, 2023 | markets.businessinsider.comRaymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)September 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.March 29, 2023 | finance.yahoo.com12 Cheap Healthcare Stocks to Buy in 2023March 9, 2023 | prnewswire.comCATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIOFebruary 28, 2023 | msn.comCatalyst Biosciences Shares Are Rallying: What's Driving The Action?February 28, 2023 | finance.yahoo.comCatalyst Biosciences Provides Corporate UpdateFebruary 27, 2023 | finance.yahoo.comGC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in HematologyFebruary 5, 2023 | morningstar.comCatalyst/Millburn Hedge Strategy IJanuary 19, 2023 | insidermonkey.com5 Stocks with the Lowest PE RatioJanuary 4, 2023 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIODecember 29, 2022 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. MergerDecember 29, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, BLI, ISO, CBIODecember 28, 2022 | benzinga.comCBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to ShareholdersNovember 16, 2022 | finance.yahoo.comCatalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)October 7, 2022 | fool.comHow Much Could This Catalyst Boost Shiba Inu in October?September 24, 2022 | seekingalpha.comCBIO Catalyst Biosciences, Inc.September 1, 2022 | finance.yahoo.comCatalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per shareAugust 25, 2022 | finance.yahoo.comCatalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per shareAugust 23, 2022 | nasdaq.comBullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this yearAugust 23, 2022 | finance.yahoo.comCatalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years agoSee More Headlines Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CBIO Company Calendar Last Earnings8/17/2023Today9/24/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CBIO CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees7Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net MarginsN/A Pretax Margin-994.21% Return on Equity-364.68% Return on Assets-230.82% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual Sales$790,000.00 Price / Sales23.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.71Miscellaneous Outstanding Shares37,970,000Free Float36,456,000Market Cap$18.65 million OptionableOptionable Beta1.02 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Nassim Usman Ph.D. (Age 63)Pres, CEO & Director Comp: $1.75MMs. Seline E. Miller CPA (Age 54)Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer Comp: $707.55kMs. Ana KaporSr. Director of Investor Relations & Corp. CommunicationsKey CompetitorsRegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIOAcer TherapeuticsNASDAQ:ACERView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 101,500 shares on 8/11/2023Ownership: 2.051%Acadian Asset Management LLCSold 115,439 shares on 8/7/2023Ownership: 0.381%Simplex Trading LLCSold 400 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions CBIO Stock - Frequently Asked Questions How have CBIO shares performed in 2023? Catalyst Biosciences' stock was trading at $0.5275 at the start of the year. Since then, CBIO shares have decreased by 6.9% and is now trading at $0.4912. View the best growth stocks for 2023 here. Are investors shorting Catalyst Biosciences? Catalyst Biosciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 165,400 shares, an increase of 61.8% from the August 15th total of 102,200 shares. Based on an average trading volume of 709,900 shares, the days-to-cover ratio is presently 0.2 days. View Catalyst Biosciences' Short Interest. When is Catalyst Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our CBIO earnings forecast. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). How often does Catalyst Biosciences pay dividends? What is the dividend yield for Catalyst Biosciences? Catalyst Biosciences announced a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be given a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date is Friday, January 13th. Read our dividend analysis for CBIO. When did Catalyst Biosciences' stock split? Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN). What is Catalyst Biosciences' stock symbol? Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO." Who are Catalyst Biosciences' major shareholders? Catalyst Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.05%), Acadian Asset Management LLC (0.38%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Catalyst Biosciences? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Biosciences' stock price today? One share of CBIO stock can currently be purchased for approximately $0.49. How much money does Catalyst Biosciences make? Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $18.65 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. How can I contact Catalyst Biosciences? Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107. This page (NASDAQ:CBIO) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.